Imagyn Laparoscopic Line Divestiture Lets Firm Focus On Oncology Devices
This article was originally published in The Gray Sheet
Executive SummaryImagyn will use the nearly $30 mil. in proceeds from the sale of its minimal access surgery (MAS) products to Conmed to help launch three new oncology and critical care products.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.